Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Investing Activities (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash from Investing Activities for 7 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 29.03% to $8.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $44.6 million, a 6713.76% increase, with the full-year FY2024 number at $17.5 million, up 970.75% from a year prior.
  • Cash from Investing Activities was $8.7 million for Q3 2025 at Pulmonx, up from $5.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $16.3 million in Q1 2025 to a low of -$29.1 million in Q4 2021.
  • A 5-year average of -$237684.2 and a median of -$727000.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 4392.11% in 2021, then soared 2143.18% in 2023.
  • Pulmonx's Cash from Investing Activities stood at -$29.1 million in 2021, then surged by 97.5% to -$727000.0 in 2022, then plummeted by 278.95% to -$2.8 million in 2023, then skyrocketed by 610.6% to $14.1 million in 2024, then plummeted by 38.07% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Cash from Investing Activities are $8.7 million (Q3 2025), $5.5 million (Q2 2025), and $16.3 million (Q1 2025).